BELLUS Health (BLU.TO) Stock Price

BELLUS Health Price

Delisted·Jun 19, 2026
1.86USD-0.12 (-6.38 %)
Last traded price

Revenue at BELLUS Health has contracted by 14.2% per year over the past 18 years to 16,000.00 USD. BELLUS Health's net margin stands at -475,500.0%, down from -23,366.7% several years earlier. The stock trades about 370% above its 52-week low.

BELLUS Health stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BELLUS Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BELLUS Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BELLUS Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BELLUS Health Stock Price History
DateBELLUS Health Price
6/19/20261.86 USD
6/18/20261.98 USD
6/17/20262.02 USD
6/16/20262.07 USD
6/15/20262.13 USD
6/12/20262.14 USD
6/11/20262.03 USD
6/10/20262.00 USD
6/9/20262.02 USD
6/8/20262.16 USD
6/5/20262.12 USD
6/4/20262.16 USD
6/3/20262.31 USD
6/2/20262.37 USD
6/1/20262.12 USD
5/29/20262.27 USD
5/28/20262.31 USD
5/27/20262.21 USD
5/26/20262.01 USD
5/25/20262.07 USD
5/22/20262.23 USD
5/21/20262.14 USD
5/20/20262.05 USD
5/19/20262.16 USD
5/15/20262.23 USD
5/14/20262.19 USD
5/13/20262.23 USD
5/12/20262.30 USD
5/11/20262.31 USD
5/8/20262.16 USD
5/7/20261.98 USD
5/6/20261.91 USD
5/5/20261.88 USD
5/4/20261.88 USD
5/1/20261.93 USD
4/30/20261.98 USD
4/29/20261.98 USD
4/28/20262.01 USD
4/27/20261.96 USD
4/24/20262.03 USD
4/23/20261.70 USD
4/22/20261.71 USD
4/21/20261.72 USD
4/20/20261.73 USD
4/17/20261.65 USD
4/16/20261.61 USD
4/15/20261.75 USD
4/14/20261.44 USD
4/13/20261.43 USD
4/10/20261.44 USD
4/9/20261.43 USD
4/8/20261.44 USD
4/7/20261.44 USD
4/6/20261.47 USD
4/2/20261.44 USD
4/1/20261.46 USD
3/31/20261.43 USD
3/30/20261.40 USD
3/27/20261.51 USD
3/26/20261.47 USD
3/25/20261.46 USD
3/24/20261.26 USD
3/23/20261.21 USD
3/20/20261.27 USD
3/19/20261.17 USD
3/18/20261.15 USD
3/17/20261.18 USD
3/16/20261.18 USD
3/13/20261.09 USD
3/12/20261.06 USD
3/11/20261.08 USD
3/10/20261.06 USD
3/9/20261.09 USD
3/6/20261.11 USD
3/5/20261.14 USD
3/4/20261.14 USD
3/3/20261.11 USD
3/2/20261.11 USD
2/27/20261.11 USD
2/26/20261.14 USD
2/25/20261.09 USD
2/24/20261.08 USD
2/23/20261.08 USD
2/20/20261.08 USD
2/19/20261.08 USD
2/18/20261.10 USD
2/17/20261.11 USD
2/13/20261.11 USD
2/12/20261.11 USD
2/11/20261.11 USD
2/10/20261.17 USD
2/9/20261.20 USD
2/6/20261.22 USD
2/5/20261.20 USD
2/4/20261.19 USD
2/3/20261.17 USD
2/2/20261.22 USD
1/30/20261.15 USD
1/29/20261.18 USD
1/28/20261.16 USD
1/27/20261.16 USD
1/26/20261.14 USD
1/23/20261.14 USD
1/22/20261.15 USD
1/21/20261.16 USD
1/20/20261.08 USD
1/19/20261.09 USD
1/16/20261.08 USD
1/15/20261.08 USD
1/14/20260.95 USD
1/13/20260.96 USD
1/12/20260.96 USD
1/9/20260.96 USD
1/8/20260.88 USD
1/7/20260.72 USD
1/6/20260.72 USD
1/5/20260.86 USD
1/2/20260.79 USD
12/31/20250.79 USD
12/30/20250.79 USD
12/29/20250.90 USD
12/24/20250.97 USD
12/23/20250.97 USD
12/22/20250.93 USD
12/19/20251.00 USD
12/18/20251.00 USD
12/17/20250.93 USD
12/16/20250.82 USD
12/15/20250.82 USD
12/12/20250.82 USD
12/11/20250.80 USD
12/10/20250.72 USD
12/9/20250.72 USD
12/8/20250.72 USD
12/5/20250.72 USD
12/4/20250.72 USD
12/3/20250.72 USD
12/2/20250.72 USD
12/1/20250.72 USD
11/28/20250.72 USD
11/27/20250.72 USD
11/26/20250.72 USD
11/25/20250.72 USD
11/24/20250.72 USD
11/21/20250.65 USD
11/20/20250.65 USD
11/19/20250.65 USD
11/18/20250.65 USD
11/17/20250.65 USD
11/14/20250.65 USD
11/13/20250.65 USD
11/12/20250.70 USD
11/11/20250.70 USD
11/10/20250.70 USD
11/7/20250.75 USD
11/6/20250.75 USD
11/5/20250.70 USD
11/4/20250.72 USD
11/3/20250.68 USD
10/31/20250.68 USD
10/30/20250.68 USD
10/29/20250.72 USD
10/28/20250.61 USD
10/27/20250.68 USD
10/24/20250.70 USD
10/23/20250.70 USD
10/22/20250.69 USD
10/21/20250.75 USD
10/20/20250.86 USD
10/17/20250.86 USD
10/16/20250.77 USD
10/15/20250.80 USD
10/14/20250.86 USD
10/10/20250.97 USD
10/9/20250.97 USD
10/8/20251.01 USD
10/7/20250.82 USD
10/6/20250.81 USD
10/3/20250.81 USD
10/2/20250.74 USD
10/1/20250.83 USD
9/30/20250.86 USD
9/29/20250.86 USD
9/26/20250.90 USD
9/25/20250.90 USD
9/24/20250.83 USD
9/23/20250.79 USD
9/22/20250.72 USD
9/19/20250.72 USD
9/18/20250.61 USD
9/17/20250.65 USD
9/16/20250.54 USD
9/15/20250.54 USD
9/12/20250.49 USD
9/11/20250.47 USD
9/10/20250.47 USD
9/9/20250.47 USD
9/8/20250.47 USD
9/5/20250.48 USD
9/4/20250.48 USD
9/3/20250.48 USD
9/2/20250.49 USD
8/29/20250.47 USD
8/28/20250.47 USD
8/27/20250.40 USD
8/26/20250.40 USD
8/25/20250.43 USD
8/22/20250.40 USD
8/21/20250.40 USD
8/20/20250.40 USD
8/19/20250.43 USD
8/18/20250.43 USD
8/15/20250.42 USD
8/14/20250.42 USD
8/13/20250.40 USD
8/12/20250.43 USD
8/11/20250.43 USD
Access this data via the Eulerpool API
Get Free API Key

BELLUS Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
20,000.00 USD
-32.94 M USD
-31.76 M USD
Jan 1, 2021
16,000.00 USD
-73.28 M USD
-71.22 M USD
Jan 1, 2022
16,000.00 USD
-77.88 M USD
-76.08 M USD
Jan 1, 2023 (e)
11,867.50 USD
-101.07 M USD
-97.09 M USD
Jan 1, 2024 (e)
11,867.50 USD
-119.53 M USD
-105.79 M USD
Jan 1, 2025 (e)
2.51 M USD
-139.19 M USD
-100.78 M USD
Jan 1, 2026 (e)
126.12 M USD
-66.51 M USD
-41.70 M USD
Jan 1, 2027 (e)
453.75 M USD
275.56 M USD
194.23 M USD

BELLUS Health Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 9:47 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
2.002.003.001.00––––––––2.00126.00453.00727.00
––50.00-66.67–––––––––6,200.00259.5260.49
-3.00-2.00–-1.00-4.00-7.00-25.00-32.00-73.00-77.00-101.00-119.00-139.00-66.00275.00–
-150.00-100.00–-100.00––––––––-6,950.00-52.3860.71–
–-1.00–-1.00-1.00-7.00-26.00-31.00-71.00-76.00-97.00-105.00-100.00-41.00194.00308.00
–––––600.00271.4319.23129.037.0427.638.25-4.76-59.00-573.1758.76
13.1713.1713.1716.2219.0733.6247.4359.0279.32115.36115.36115.36115.36115.36115.36115.36
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BELLUS Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BELLUS Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BELLUS Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BELLUS Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BELLUS Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BELLUS Health stock margins

The BELLUS Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BELLUS Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BELLUS Health.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
-25,466.67 %
-23,366.67 %
Jan 1, 2019
0.00 %
-85,766.67 %
-86,700.00 %
Jan 1, 2020
0.00 %
-164,700.00 %
-158,800.00 %
Jan 1, 2021
0.00 %
-458,024.95 %
-445,149.95 %
Jan 1, 2022
0.00 %
-486,768.75 %
-475,500.00 %
Jan 1, 2023 (e)
0.00 %
-851,634.04 %
-818,144.26 %
Jan 1, 2024 (e)
0.00 %
-1.01 M %
-891,453.55 %
Jan 1, 2025 (e)
0.00 %
-5,552.02 %
-4,020.07 %

BELLUS Health Stock Revenue, EBIT, Earnings per Share

The BELLUS Health earnings per share therefore indicates how much revenue BELLUS Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 USD
-0.23 USD
-0.21 USD
Jan 1, 2019
0.00 USD
-0.54 USD
-0.55 USD
Jan 1, 2020
0.00 USD
-0.56 USD
-0.54 USD
Jan 1, 2021
0.00 USD
-0.92 USD
-0.90 USD
Jan 1, 2022
0.00 USD
-0.68 USD
-0.66 USD
Jan 1, 2023 (e)
0.00 USD
-0.88 USD
-0.84 USD
Jan 1, 2024 (e)
0.00 USD
-1.04 USD
-0.92 USD
Jan 1, 2025 (e)
0.02 USD
-1.21 USD
-0.87 USD

BELLUS Health business model & stock analysis

BELLUS Health Inc. is a Canadian biotechnology company that offers a wide range of healthcare products and services aimed at treating chronic diseases and improving patients' quality of life. The company was founded in 1993 and is headquartered in Laval, Quebec, Canada.

BELLUS Health SWOT Analysis

Strengths

BELLUS Health Inc boasts a robust pipeline consisting of novel pharmaceutical products targeting various therapeutic areas. This diverse portfolio positions the company favorably for future revenue growth and market expansion.

The company has a solid track record in research and development, with an experienced team of scientists and experts. This expertise enables BELLUS Health Inc to consistently create and advance innovative drug candidates, enhancing its competitive advantage in the pharmaceutical industry.

BELLUS Health Inc has successfully formed strategic partnerships and collaborations with renowned pharmaceutical companies and research institutions. These relationships not only provide access to additional resources and expertise but also create opportunities for knowledge-sharing and potential joint ventures.

Weaknesses

The success of BELLUS Health Inc heavily relies on the performance and approval of its key product candidates. Any setbacks or delays in these candidate drugs may significantly impact the company's financial prospects and growth potential.

Despite its promising pipeline, BELLUS Health Inc may face financial constraints due to its relatively limited resources compared to larger pharmaceutical players. This may limit its ability to fully exploit market opportunities and execute ambitious growth strategies.

Opportunities

The pharmaceutical industry is witnessing an increasing demand for innovative therapies that address unmet medical needs. BELLUS Health Inc can capitalize on this opportunity by leveraging its pipeline to offer novel solutions and gain market share.

Expanding into emerging markets presents an opportunity for BELLUS Health Inc to tap into new patient populations and revenue streams. By adapting its products to suit local market needs and establishing strategic partnerships, the company can benefit from the rising healthcare expenditures in these regions.

Threats

BELLUS Health Inc operates in a highly competitive environment, with numerous pharmaceutical companies vying for market dominance. The company must continually innovate and differentiate itself to stay ahead of competitors and retain its market share.

The regulatory process for drug approval can be complex and stringent, posing risks to the commercialization timelines of BELLUS Health Inc's products. Additionally, market acceptance and pricing negotiations post-approval can impact the company's revenue generation.

BELLUS Health Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BELLUS Health historical P/E ratio, EBIT multiple, and P/S ratio

BELLUS Health annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BELLUS Health shares outstanding

The number of shares of BELLUS Health was 115.36 M in 2025. This indicates how many shares BELLUS Health is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
33.62 M Stocks
Jan 1, 2019
47.43 M Stocks
Jan 1, 2020
59.02 M Stocks
Jan 1, 2021
79.32 M Stocks
Jan 1, 2022
115.36 M Stocks
Jan 1, 2023 (e)
115.36 M Stocks
Jan 1, 2024 (e)
115.36 M Stocks
Jan 1, 2025 (e)
115.36 M Stocks

BELLUS Health stock splits

In BELLUS Health's history, there have been no stock splits.
Price targets and forecasts for BELLUS Health are not yet available.

BELLUS Health Analyst Rating Actions

DateFirmActionRatingReliability
5/15/2023
RBC Capital
RBC Capital
MaintainedSector PerformPerform52
5/14/2023
RBC Capital
RBC Capital
MaintainedSector PerformPerform52
4/19/2023
RBC Capital
RBC Capital
DowngradeOutperformPerform52
4/19/2023
Jefferies
Jefferies
DowngradeBuyHold47
4/18/2023
RBC Capital
RBC Capital
DowngradeOutperformPerform52
4/18/2023
Jefferies
Jefferies
DowngradeBuyHold47
4/18/2023
Evercore ISI Group
Evercore ISI Group
DowngradeOutperformIn Line62
4/17/2023
Evercore ISI Group
Evercore ISI Group
DowngradeOutperformIn Line62
3/22/2023
RBC Capital
RBC Capital
MaintainedOutperform52
3/22/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

BELLUS Health Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/19/2024-0.26USD-0.00USD-2023 Q4
8/8/2023-0.03USD-1.24 MUSD-2023 Q2
5/9/2023-0.03USD-1.24 MUSD-2023 Q1
2/21/2023-0.18USD-618,642.00USD-2022 Q4
11/14/2022-0.17USD-3,552.00USD-2022 Q3
8/10/2022-0.18USD-2,364.00USD-2022 Q2
5/11/2022-0.20USD-0.00USD-2022 Q1
2/23/2022-0.22USD-7,104.00USD-2021 Q4
11/10/2021-0.21USD-7,104.00USD-2021 Q3
8/11/2021-0.21USD-3,725.00USD-2021 Q2

BELLUS Health shareholder structure

% Name
10.79465%
RA Capital Management, LP
RA Capital Management, LP
7.70728%
Perceptive Advisors LLC
Perceptive Advisors LLC
7.00349%
Goldman Sachs & Company, Inc.
Goldman Sachs & Company, Inc.
5.79809%
Pictet Asset Management Ltd.
Pictet Asset Management Ltd.
4.59744%
Commodore Capital LP
Commodore Capital LP
4.28032%
Power Corporation of Canada
Power Corporation of Canada
...

BELLUS Health Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.7%
Float Shares
-
Shares Outstanding
-

BELLUS Health Executives and Management Board

13 members · avg. age 60 · 15 % women

RB

Mr. Roberto Bellini (42)

President, Chief Executive Officer, Director · since 2009

1.78 M USD

Management

CB

Dr. Catherine Bonuccelli

Chief Medical Officer

1.23 M USD
DG

Dr. Denis Garceau

Chief Scientific Officer · since 2021

869,424.00 USD
TM

Mr. Tony Matzouranis

Senior Vice President - Business Development · since 2021

626,305.00 USD
RB

Mr. Ramzi Benamar

Chief Financial Officer

607,333.00 USD
SR

Mr. Sebastien Roy (46)

Corporate Secretary

–

Board of Directors

FB

Dr. Francesco Bellini (75)

Chairman of the Board

418,229.00 USD
PL

Mr. Pierre Larochelle (50)

Lead Independent Director

231,604.00 USD
WM

Dr. William Mezzanotte (63)

Independent Director

199,826.00 USD
FB

Mr. Franklin Berger (72)

Independent Director

199,280.00 USD
JR

Mr. Joseph Rus (76)

Independent Director

199,280.00 USD
YB

Dr. Youssef Bennani (61)

Independent Director

170,747.00 USD

Frequently asked questions about BELLUS Health

The business model of BELLUS Health Inc is focused on developing and commercializing innovative therapeutics to address unmet medical needs. BELLUS Health Inc primarily focuses on the development of drugs that target chronic cough and other hypersensitization-related disorders. With a strong emphasis on research and development, BELLUS Health Inc aims to leverage its expertise in drug discovery and advance its pipeline of potential therapeutic candidates. The company's commitment to scientific rigor and strategic partnerships contributes to its innovative approach to bringing novel treatments to patients in need. BELLUS Health Inc's business model revolves around creating value through the development and commercialization of pharmaceutical products.

BELLUS Health Inc primarily operates in the biopharmaceutical industry.

The main competitors of BELLUS Health Inc in the market include pharmaceutical companies such as Pfizer, Johnson & Johnson, and Novartis. These companies are also involved in the research, development, and production of various drugs and treatments. By consistently monitoring the market activities of these competitors, BELLUS Health Inc can stay competitive and continually innovate in order to meet the needs and demands of its customers.

BELLUS Health Inc is a Canadian biopharmaceutical company focused on the development of innovative therapies for conditions affecting the kidney and central nervous system. Founded in 1993, BELLUS Health has a strong history of research and collaboration, aiming to address unmet medical needs. The company has a diverse pipeline of drug candidates, including its lead product candidate, BLU-5937, which aims to treat chronic cough. BELLUS Health is committed to advancing therapies that improve patients' quality of life and has garnered recognition for its dedication to scientific excellence and innovation in the field of biopharmaceuticals.

BELLUS Health Inc has achieved significant milestones in its journey. The company successfully completed its Phase 2a clinical study for BLU-5937, a treatment for chronic cough. Additionally, BELLUS Health Inc received Fast Track designation from the U.S. FDA for BLU-5937, indicating its potential to address a significant unmet medical need. Furthermore, the company entered into a collaboration agreement with NEOMED-LABS to support the development of BLU-5937. This collaboration enhances BELLUS Health Inc's clinical development capabilities and expertise. These achievements reflect the company's commitment to advancing innovative solutions for patients globally, underscoring its position in the healthcare industry.

BELLUS Health Inc is primarily present in North America, with a focus on Canada and the United States.

BELLUS Health Inc represents values of innovation, integrity, and excellence in the biopharmaceutical industry. The company's corporate philosophy is centered around improving the health and well-being of individuals by developing and commercializing novel therapies. BELLUS Health Inc believes in conducting business with transparency, adhering to ethical practices, and nurturing a collaborative environment for growth and success. With a focus on research and development, the company strives to provide innovative solutions to address unmet medical needs. BELLUS Health Inc's commitment to advancing healthcare through scientific advancement sets them apart in the industry.

10 analysts currently rate the BELLUS Health stock: 6 recommend buying, 4 holding and 0 selling.

BELLUS Health Analyst Price Targets 2026

Converted at the current exchange rate, the BELLUS Health share trades at 1.61 EUR (1.86 USD).

The BELLUS Health share (BLU.TO) is listed on 5 stock exchanges, including: NASDAQ (BLU), Frankfurt (BHN0.F), München (BHN0.MU), Düsseldorf (BHN0.DU), London (0A4U.L).

BELLUS Health Inc is a biopharmaceutical company that operates in the fields of dermatology, plant medicine, and neurology. The company's goal is to develop new treatment methods for diseases and contribute to improving the quality of life for patients. The company focuses on high standards in researching and developing medications and therapies. BELLUS Health Inc offers a wide range of products in dermatology, including topical creams and solutions for treating skin conditions. One example is the medication Solabegron, used to treat rosacea. Another important product line in dermatology is BELLUS Health Inc's medical devices for laser therapy of acne. In plant medicine, BELLUS Health Inc researches natural remedies, mainly active substances derived from plant extracts. A significant medication in this field is Kinetin, used for cosmetic treatment of skin aging. BELLUS Health Inc also focuses on treating central nervous system diseases. The company conducts intensive research in developing new approaches for treating neurodegenerative diseases such as Alzheimer's and Parkinson's. BELLUS Health Inc employs innovative therapy concepts, such as antibody-based treatments. Alongside research and development, distributing medications and medical devices forms an important business area for BELLUS Health Inc. The company collaborates closely with pharmacies and hospitals to provide patients with access to the latest treatment methods. BELLUS Health Inc also has a network of strategic partners in the pharmaceutical industry and scientific field. The company works closely with these partners to achieve synergies and translate research findings into marketable products and therapies faster. In conclusion, BELLUS Health Inc is a company with a diverse product portfolio in the field of medicine and biosciences. The company prioritizes collaboration with partners and research institutions to develop innovative treatment methods and therapies. Cooperation with pharmacies and hospitals allows the company to facilitate patient access to the latest medical developments.

The revenue cannot currently be calculated for BELLUS Health.

The profit cannot currently be calculated for BELLUS Health.

The P/E ratio cannot be calculated for BELLUS Health at the moment.

The P/S cannot be calculated for BELLUS Health currently.

The Eulerpool Quality Score for BELLUS Health is 2/10.

The ISIN of BELLUS Health is CA07987C2040. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of BELLUS Health is A2PQKK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of BELLUS Health is BLU.TO. The ticker symbol is used to trade BELLUS Health shares on the stock exchange.

BELLUS Health paid dividends every year for the past 0 years.

BELLUS Health is assigned to the 'Health' sector.

The dividends of BELLUS Health are distributed in USD.

All fundamentals and in-depth analysis of BELLUS Health

Our stock analysis for BELLUS Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BELLUS Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BELLUS Health Stock
BELLUS Health Revenue→
BELLUS Health Stock
BELLUS Health Net Income→
BELLUS Health Stock
BELLUS Health P/E→
BELLUS Health Stock
BELLUS Health P/S→
BELLUS Health Stock
BELLUS Health EBIT→
BELLUS Health Stock
BELLUS Health Dividend→
BELLUS Health Stock
BELLUS Health Directors Dealings→
BELLUS Health Stock
BELLUS Health Stocks→
BELLUS Health Stock
BELLUS Health Market capitalization→
BELLUS Health Stock
BELLUS Health Debt→
BELLUS Health Stock
BELLUS Health Liabilities→
BELLUS Health Stock
BELLUS Health Equity→
BELLUS Health Stock
BELLUS Health AAQS→
BELLUS Health Stock
BELLUS Health Employees→
BELLUS Health Stock
BELLUS Health ROE→
BELLUS Health Stock
BELLUS Health ROA→
BELLUS Health Stock
BELLUS Health ROCE→
BELLUS Health Stock
BELLUS Health News→
BELLUS Health Stock
BELLUS Health Analyst Price Targets→